Article Details

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 ...

Retrieved on: 2025-05-08 13:53:37

Tags for this article:

Click the tags to see associated articles and topics

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 .... View article details on hiswai:

Excerpt

(Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo